Found: 15
Select item for more details and to access through your institution.
Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 14, p. 1855, doi. 10.3390/cells12141855
- By:
- Publication type:
- Article
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 22, p. 3663, doi. 10.3390/cells11223663
- By:
- Publication type:
- Article
Macrophage Profiling in Head and Neck Cancer to Improve Patient Prognosis and Assessment of Cancer Cell–Macrophage Interactions Using Three-Dimensional Coculture Models.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 16, p. 12813, doi. 10.3390/ijms241612813
- By:
- Publication type:
- Article
ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.
- Published in:
- Cancer Cell International, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12935-023-03196-y
- By:
- Publication type:
- Article
Primary non-Hodgkin's lymphoma of the duodenum. Case report and literature review.
- Published in:
- 1984
- By:
- Publication type:
- journal article
Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms.
- Published in:
- Biology (2079-7737), 2020, v. 9, n. 8, p. 218, doi. 10.3390/biology9080218
- By:
- Publication type:
- Article
Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.780654
- By:
- Publication type:
- Article
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12 , 512.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11 , 1093.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
RTK Inhibitors in Melanoma: From Bench to Bedside.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1685, doi. 10.3390/cancers13071685
- By:
- Publication type:
- Article
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12 , 512
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis.
- Published in:
- Cancers, 2020, v. 12, n. 5, p. 1323, doi. 10.3390/cancers12051323
- By:
- Publication type:
- Article
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma.
- Published in:
- Cancers, 2020, v. 12, n. 2, p. 512, doi. 10.3390/cancers12020512
- By:
- Publication type:
- Article
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.
- Published in:
- Cancers, 2019, v. 11, n. 8, p. 1093, doi. 10.3390/cancers11081093
- By:
- Publication type:
- Article
PRIMA-1 and PRIMA-1<sup>Met</sup> (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.
- Published in:
- Cancers, 2017, v. 9, n. 12, p. 172, doi. 10.3390/cancers9120172
- By:
- Publication type:
- Article